Newer antidepressants and panic disorder: a meta-analysis

@article{Andrisano2013NewerAA,
  title={Newer antidepressants and panic disorder: a meta-analysis},
  author={C. Andrisano and A. Chiesa and A. Serretti},
  journal={International Clinical Psychopharmacology},
  year={2013},
  volume={28},
  pages={33–45}
}
Selective serotonin reuptake inhibitors and venlafaxine are currently considered as first-line agents for patients with panic disorder (PD). However, a systematic comparison of newer antidepressants for the treatment of PD is lacking thus far. Eligible studies focusing on PD patients treated with newer antidepressants were entered in the Cochrane Collaboration Review Manager. Our primary outcome measure was the mean change in panic symptoms from the baseline to the endpoint in patients treated… Expand
Pharmacological Therapy in Panic Disorder: Current Guidelines and Novel Drugs Discovery for Treatment-resistant Patient
TLDR
The importance of immediate and proper treatment, the gap in the current management of PD with special emphasis on pharmacotherapy, and evidence regarding the novel anti-panic drugs including the drugs in developments such as metabotropic glutamate (mGlu 2/3) agonist and levetiracetam are covered. Expand
Pharmacological Treatment of Panic Disorder with Non-Selective Drugs
TLDR
It is important to use existing scientific evidences regarding effectiveness, tolerability and safety, combined with clinical experience, to plan a rational treatment sequence for panic disorder patients. Expand
Short-Term Efficacy and Tolerability of Paroxetine Versus Placebo for Panic Disorder: A Meta-Analysis of Randomized Controlled Trials
TLDR
Paroxetine is an effective and well-tolerated short-term treatment for adults with panic disorder and the incidence of any treatment-emergent adverse events (TEAEs) was lower than the placebo group. Expand
Antidepressants versus placebo for panic disorder in adults.
TLDR
Low-quality evidence was found that revealed a benefit for antidepressants as a group in comparison with placebo in terms of efficacy measured as failure to respond, and treatment acceptability, measured by total number of dropouts for any reason. Expand
[Panic disorder: clinical phenomena and treatment options].
  • Y. Sivolap
  • Medicine
  • Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • 2017
TLDR
Clinically proven efficacy in the treatment of panic disorder have benzodiazepines, tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reptake inhibitors. Expand
Pharmacological Treatment with the Selective Serotonin Reuptake Inhibitors
TLDR
In this chapter, efficacy studies, common side effects and drug interactions of the SSRI are described as well as general recommendations for their clinical use in PD. Expand
Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: A systematic review and network meta-analysis.
TLDR
Escitalopram and venlafaxine as well as benzodiazepines may be effective choices as treatments for PD with relatively good acceptability, which still needs to be confirmed by high-quality RCTs. Expand
Personalized medicine in panic disorder: where are we now? A meta-regression analysis
TLDR
Limited support for the moderating effects of sociodemographic and clinical variables on the short-term pharmacotherapy for PD is found, and higher age at the beginning of trials was significantly associated with a higher rate of dropouts because of side effects during trials with paroxetine. Expand
A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder
TLDR
This proof-of-concept RCT did not support the efficacy of this treatment strategy for SSRI-resistant PD, and the relatively low average dose of quetiapine XR used was generally well-tolerated. Expand
A pharmacological approach to panic disorder during pregnancy
  • F. Uguz
  • Medicine
  • The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2016
Abstract Anxiety disorders and pregnancy may occur concurrently in some women. Although, several epidemiological or clinical studies about anxiety disorders in pregnancy exist, data on theirExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 103 REFERENCES
New treatment options for panic disorder: clinical trials from 2000 to 2010
TLDR
A systematic review of the literature regarding the pharmacological treatment of Panic disorder in the last 10 years found that SSRIs and SNRIs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications. Expand
A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.
TLDR
Evidence that the serotonergic system plays a significant role in the anti-panic properties of these two SSRIs is supported, and paroxetine and citalopram show similar anti- panic properties and a good tolerability profile. Expand
Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
TLDR
Reboxetine was effective and well tolerated in the treatment of panic disorder and improvement in Hamilton Rating Scale for Depression, Hopkins Symptom Checklist-90, and Sheehan Disability Scale scores were greater in the reboxetine group compared with the placebo group. Expand
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies
TLDR
The authors explore the anxiolytic mechanism of action of this antidepressant drug class and the preclinical studies that are being developed to clarify the etiopathogenic mechanisms of PD and, more precisely, the role of the serotoninergic system in this pathogenesis. Expand
An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.
TLDR
An effect-size analysis of controlled studies of treatments for panic disorder revealed no significant differences between SSRIs and older antidepressants in terms of efficacy or tolerability in short-term trials. Expand
Mirtazapine versus fluoxetine in the treatment of panic disorder.
  • L. Ribeiro, J. Busnello, +4 authors F. Kapczinski
  • Medicine, Biology
  • Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • 2001
TLDR
Results suggest that mirtazapine has properties that make it attractive for the treatment of panic disorder and shows no significant differences between the two treatment groups in number of panic attacks. Expand
Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study.
TLDR
Tritiated platelet imipramine and paroxetine bindings revealed significantly lower maximal binding for patients with panic disorder in comparison with controls, and ParoxETine Bmax showed a trend to increase in the direction of control values by the end of the trial. Expand
Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
TLDR
Results support the safety and efficacy of sertraline for the short-term treatment of patients with panic disorder. Expand
Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study.
TLDR
The results showed a greater effect of paroxetine on panic attacks than reboxettine, while no differences for anticipatory anxiety and avoidance were found, suggesting a different role of noradrenaline and serotonin in the treatment of PD. Expand
Combined Paroxetine and Clonazepam Treatment Strategies Compared to Paroxetine Monotherapy for Panic Disorder
TLDR
Combined treatment with paroxetine and clonazepam resulted in more rapid response than with the SSRI alone, but there was no differential benefit beyond the initial few weeks of therapy. Expand
...
1
2
3
4
5
...